Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced that it has distributed to shareholders a mid-year update letter reviewing the company’s recent progress and clinical plans for the remainder of 2018 and 2019.
Meet RESI’s Network of Global Investors and Channel Partners
This fall, the Redefining Early Stage Investments Conference (RESI) will expand to include tech hubs and companies from the First Coast: DC, MD, PA, NJ, NY, RI, CT, and MA. RESI invites earliest stage companies from the discovery stage through venture stage: companies seeking grants, seed, angel, series A, and series B funding.
As a client/partner of BioHealth Innovation and/or an early stage biohealth start-up in the BioHealth Capital Region, you can attend the RESI Boston September Conference at a reduced rate – $300 each ticket for the first 5 signups; each ticket valued at $1,295.
RESI is a partnering vehicle for you to connect with global investors and strategic partners. You’ll have an opportunity to showcase your technology and assets in a poster board format with our table in the exhibit hall. You can participate in partnering and networking all day, and explore the exhibit hall, investor panels and entrepreneur workshops.
Email BioHealth Innovation for the Discount Code and Register Now
$300 for Tech Hub Members Includes:
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced today that the first healthy subjects have been dosed in a Phase 1 clinical study of BT-11, a first-in-class, orally-administered, molecule targeting the LANCL2 pathway. The Phase 1 study is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study intended to enroll up to 70 healthy volunteers to evaluate the safety and tolerability of BT-11. BT-11 is in development for treatment of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD).
As a BARDA DRIVe Accelerator, the Center for Biotechnology is pleased to announce that the simplified funding application process, called EZ BAA, is now open. Medical product developers, research teams, and companies offering disruptive solutions to health security threats are invited to submit abstracts using this simplified EZ BAA process.
Applications accepted through this streamlined process must offer transformative innovation, products and technologies to protect Americans from health security threats. This application process is a business friendly simple abstract.
In-scope priority areas include products and solutions to reduce illness and death from sepsis as part of DRIVe’s Solving Sepsis initiative; technologies and processes to identify infections and exposures to biological and other health threats, as outlined in the Early Notification to Act, Control, and Treat (ENACT) initiative; and tools and techniques to mitigate the damages and loss of life associated with catastrophic events.
Thursday, Septmember 27, 20184:00-7:00 PM
Enjoy an evening with food, fun and lively conversation at Biotech and Beer. Meet old friends and new colleagues in the life science community. Complimentary admission for any bioscience company employees, and university students and researchers with advanced registration. All others may purchase tickets.
Amazon has been keeping 20 cities guessing about its plans for a $5 billion second headquarters, with sites in Northern Virginia, Washington, and Montgomery County in the mix.
Who are the leading angel investors startup entrepreneurs should be pitching right now? How do you connect with them?
Effective fundraising for startups isn’t about how many people and firms you can blast your opportunity out to. It’s about getting in front of the right investors, with a strong pitch deck. A recent DocSend survey shows successfully funded startups contacted an average of just 58 investors, made 40 meetings, and took just 12.5 weeks to close their funding round.
Fairfax health technology company Vibrent Health hosted Congressman Gerry Connolly (D-VA, 11th District) at the company’s new offices for a town hall style meeting today, to talk about digital health initiatives, health care access, immigration issues and other topics of interest to Vibrent’s 140 employees.
“Congressman Connolly understands the importance of integrating health data from various sources to promote the best outcomes for individuals and for public health,” said Vibrent Health Founder and CEO Praduman “PJ” Jain. “We are eager to work with our leaders in government to continue developing digital health technology that advances health research and empowers people to live healthier lives.”
The 2018 UEDA Awards of Excellence finalists have been chosen following an extremely close competition this year. Higher education institutions and organizations across North America submit nominations annually for innovative programs that focus on developing economic prosperity in their communities and beyond. A panel of university and economic development professionals have chosen 24 finalists from the group of nominated projects.
U.S. Senator Ben Cardin (D-Md.), Ranking Member of the U.S. Senate Committee on Small Business & Entrepreneurship, today announced several provisions in the 2019 National Defense Authorization Act (NDAA) specifically focused on supporting small businesses in Maryland and nationwide. The annual defense funding bill passed the Senate Wednesday.
